<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39325762</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The heat shock protein 90 inhibitor RGRN-305 attenuates SARS-CoV-2 spike protein-induced inflammation in vitro but lacks effectiveness as COVID-19 treatment in mice.</ArticleTitle><Pagination><StartPage>e0310915</StartPage><MedlinePgn>e0310915</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0310915</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0310915</ELocationID><Abstract><AbstractText>The inhibition of heat shock protein 90 (HSP90), a molecular chaperone, has been proposed to be a potential novel treatment strategy for Coronavirus disease 2019 (COVID-19). In contrast to other studies, our data demonstrated that RGRN-305, a HSP90 inhibitor, exacerbated the cytopathic effect and did not reduce the viral shedding in VeroE6-hTMPRSS2 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Likewise in a murine model of SARS-CoV-2, transgenic mice treated orally with RGRN-305 exhibited reduced survival by the end of the experiment (day 12) as 14% (1/7) survived compared to 63% (5/8) of those treated with drug-vehicle. Animal weight was not reduced by the RGRN-305 treatment. Interestingly, we demonstrated that inhibition of HSP90 by RGRN-305 significantly dampened the inflammatory response induced by SARS-CoV-2 spike protein in human macrophage-like cells (U937) and human lung epithelial cells (A549). Measured by quantitative real-time PCR, the mRNA expression of the proinflammatory cytokines TNF, IL1B and IL6 were significantly reduced. Together, these data suggest that HSP90 inhibition by RGRN-305 exacerbates the SARS-CoV-2 infection in vitro and reduces the survival of mice infected with SARS-CoV-2, but exhibits strong anti-inflammatory properties. This data shows that while RGRN-305 may be helpful in a 'cytokine storm', it has no beneficial impact on viral replication or survival in animals as a monotherapy. Further animal studies with HSP90 inhibitors in combination with an anti-viral drug may provide additional insights into its utility in viral infections and whether HSP90 inhibition may continue to be a potential treatment strategy for COVID-19 disease.</AbstractText><CopyrightInformation>Copyright: © 2024 Ben Abdallah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ben Abdallah</LastName><ForeName>Hakim</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4610-5428</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Aarhus University Hospital, Aarhus N, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marino</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idorn</LastName><ForeName>Manja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S Reinert</LastName><ForeName>Line</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bregnhøj</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Aarhus University Hospital, Aarhus N, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paludan</LastName><ForeName>Søren Riis</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Biomedicine, Aarhus University, Aarhus C, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johansen</LastName><ForeName>Claus</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Aarhus University Hospital, Aarhus N, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018841">HSP90 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018841" MajorTopicYN="Y">HSP90 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="Y">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal’s policy and the authors of this manuscript have the following competing interests: H.B.A has received research grants from Aage Bangs Fund and participated in clinical trials sponsored by Galderma, Regranion and UCB. C.J. has served as a paid speaker for LEO Pharma, Eli Lilly and L’Oréal This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325762</ArticleId><ArticleId IdType="pmc">PMC11426470</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0310915</ArticleId><ArticleId IdType="pii">PONE-D-24-13908</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. Jama. 2020;324(8):782–93. Epub 2020/07/11. doi: 10.1001/jama.2020.12839 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54. Epub 2020/10/08. doi: 10.1038/s41579-020-00459-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20(5):270–84. Epub 2022/04/01. doi: 10.1038/s41579-022-00713-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74. Epub 2020/04/30. doi: 10.1038/s41577-020-0311-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0311-8</ArticleId><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):132. Epub 2021/11/16. doi: 10.1186/s40249-021-00915-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-021-00915-3</ArticleId><ArticleId IdType="pmc">PMC8590867</ArticleId><ArticleId IdType="pubmed">34776011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubkowska A, Pluta W, Strońska A, Lalko A. Role of Heat Shock Proteins (HSP70 and HSP90) in Viral Infection. International journal of molecular sciences. 2021;22(17). Epub 2021/09/11. doi: 10.3390/ijms22179366 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179366</ArticleId><ArticleId IdType="pmc">PMC8430838</ArticleId><ArticleId IdType="pubmed">34502274</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller R, Taguwa S, Frydman J. Broad action of Hsp90 as a host chaperone required for viral replication. Biochim Biophys Acta. 2012;1823(3):698–706. Epub 2011/12/14. doi: 10.1016/j.bbamcr.2011.11.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2011.11.007</ArticleId><ArticleId IdType="pmc">PMC3339566</ArticleId><ArticleId IdType="pubmed">22154817</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Xu LD, Zhang F, Liang QZ, Jiao Y, Shi FS, et al.. Heat shock protein 90 facilitates SARS-CoV-2 structural protein-mediated virion assembly and promotes virus-induced pyroptosis. The Journal of biological chemistry. 2023;299(5):104668. Epub 2023/04/04. doi: 10.1016/j.jbc.2023.104668 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.104668</ArticleId><ArticleId IdType="pmc">PMC10066589</ArticleId><ArticleId IdType="pubmed">37011862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyler E, Mösbauer K, Franke V, Diag A, Gottula LT, Arsiè R, et al.. Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy. iScience. 2021;24(3):102151. doi: 10.1016/j.isci.2021.102151</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102151</ArticleId><ArticleId IdType="pmc">PMC7866843</ArticleId><ArticleId IdType="pubmed">33585804</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkrig J, Stanifer M, Mateus A, Mitosch K, Barrio-Hernandez I, Rettel M, et al.. SARS-CoV-2 infection remodels the host protein thermal stability landscape. Mol Syst Biol. 2021;17(2):e10188. Epub 2021/02/17. doi: 10.15252/msb.202010188 .</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.202010188</ArticleId><ArticleId IdType="pmc">PMC7885171</ArticleId><ArticleId IdType="pubmed">33590968</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Chu H, Liu X, Chiu MC, Zhao X, Wang D, et al.. Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target. Emerg Microbes Infect. 2020;9(1):2663–72. Epub 2020/11/13. doi: 10.1080/22221751.2020.1850183 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1850183</ArticleId><ArticleId IdType="pmc">PMC7751432</ArticleId><ArticleId IdType="pubmed">33179566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel W, Noerenberg M, Cerikan B, Chen H, Järvelin AI, Kammoun M, et al.. Global analysis of protein-RNA interactions in SARS-CoV-2-infected cells reveals key regulators of infection. Mol Cell. 2021;81(13):2851–67.e7. Epub 2021/06/13. doi: 10.1016/j.molcel.2021.05.023 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2021.05.023</ArticleId><ArticleId IdType="pmc">PMC8142890</ArticleId><ArticleId IdType="pubmed">34118193</ArticleId></ArticleIdList></Reference><Reference><Citation>Goswami R, Russell VS, Tu JJ, Hughes P, Kelly F, Langel SN, et al. Oral Hsp90 inhibitor, SNX-5422, attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. bioRxiv. 2021:2021.02.23.432479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579697</ArticleId><ArticleId IdType="pubmed">34786537</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al.. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–80.e8. Epub 2020/03/07. doi: 10.1016/j.cell.2020.02.052 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuto H, Komiya K, Yamasue M, Uchida S, Ogura T, Mukae H, et al.. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Sci Rep. 2020;10(1):20935. Epub 2020/12/03. doi: 10.1038/s41598-020-78054-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-78054-2</ArticleId><ArticleId IdType="pmc">PMC7708623</ArticleId><ArticleId IdType="pubmed">33262415</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al.. Dexamethasone in Hospitalized Patients with Covid-19. The New England journal of medicine. 2021;384(8):693–704. Epub 2020/07/18. doi: 10.1056/NEJMoa2021436 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH. Coronavirus disease (COVID-19): Corticosteroids, including dexamethasone 2023 [updated 28 March 2023; cited 2023 14 November 2023]. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-dexamethasone#:~:text=Corticosteroids%20are%20lifesaving%20medicines%20recommended,%2Dsevere*%20COVID%2D19.</Citation></Reference><Reference><Citation>Oladunni FS, Park JG, Pino PA, Gonzalez O, Akhter A, Allué-Guardia A, et al.. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020;11(1):6122. Epub 2020/12/02. doi: 10.1038/s41467-020-19891-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19891-7</ArticleId><ArticleId IdType="pmc">PMC7705712</ArticleId><ArticleId IdType="pubmed">33257679</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, et al.. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21(11):1327–35. Epub 2020/08/26. doi: 10.1038/s41590-020-0778-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0778-2</ArticleId><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W, Yang J, Bi Z, He C, Lei H, Yu W, et al.. A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome. Signal Transduct Target Ther. 2021;6(1):1. Epub 2021/01/02. doi: 10.1038/s41392-020-00451-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00451-w</ArticleId><ArticleId IdType="pmc">PMC7775436</ArticleId><ArticleId IdType="pubmed">33384407</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee A, Dimitropoulou C, Drakopanayiotakis F, Antonova G, Snead C, Cannon J, et al.. Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am J Respir Crit Care Med. 2007;176(7):667–75. Epub 2007/07/07. doi: 10.1164/rccm.200702-291OC .</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200702-291OC</ArticleId><ArticleId IdType="pmc">PMC1994236</ArticleId><ArticleId IdType="pubmed">17615388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bregnhøj A, Thuesen KKH, Emmanuel T, Litman T, Grek CL, Ghatnekar GS, et al.. HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study. The British journal of dermatology. 2022;186(5):861–74. Epub 2021/11/09. doi: 10.1111/bjd.20880 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.20880</ArticleId><ArticleId IdType="pubmed">34748646</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenderup K, Rosada C, Gavillet B, Vuagniaux G, Dam TN. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm Venereol. 2014;94(6):672–6. Epub 2014/03/08. doi: 10.2340/00015555-1838 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/00015555-1838</ArticleId><ArticleId IdType="pubmed">24604074</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Abdallah H, Bregnhøj A, Ghatnekar G, Iversen L, Johansen C. Heat shock protein 90 inhibition attenuates inflammation in models of atopic dermatitis: a novel mechanism of action. Frontiers in immunology. 2023;14:1289788. Epub 2024/01/26. doi: 10.3389/fimmu.2023.1289788 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1289788</ArticleId><ArticleId IdType="pmc">PMC10808526</ArticleId><ArticleId IdType="pubmed">38274815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Abdallah H, Seeler S, Bregnhøj A, Ghatnekar G, Kristensen LS, Iversen L, et al.. Heat shock protein 90 inhibitor RGRN-305 potently attenuates skin inflammation. Frontiers in immunology. 2023;14:1128897. Epub 2023/02/25. doi: 10.3389/fimmu.2023.1128897 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1128897</ArticleId><ArticleId IdType="pmc">PMC9941631</ArticleId><ArticleId IdType="pubmed">36825010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Abdallah H ET, Ghatnekar G, Johansen C, Iversen L. Efficacy and Safety of a HSP90 inhibitor (RGRN-305) in Hidradenitis Suppurativa: A Double-blind, Placebo-controlled Randomized Clinical Trial. JAMA dermatology. 2023;(ACCEPTED).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10701664</ArticleId><ArticleId IdType="pubmed">38055242</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>